GALWAY, Ireland — November 18, 2025 — Leads & Copy — Medtronic plc (NYSE: MDT) announced its second quarter (Q2) financial results for fiscal year 2026 (FY26), which ended on October 24, 2025. The healthcare technology company reported worldwide revenue of $9.0 billion, a 6.6% increase as reported and a 5.5% increase on an organic basis. GAAP diluted earnings per share (EPS) were $1.07, up 8%, while non-GAAP diluted EPS were $1.36, also up 8%. The company is raising its FY26 guidance to 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66.
According to the release, revenue growth was strongest in the Cardiovascular Portfolio, which saw an increase of 10.8% as reported and 9.3% organically, the strongest in more than a decade, excluding the pandemic. This included a mid-teens increase in Cardiac Rhythm & Heart Failure, a high-single digit increase in Structural Heart & Aortic, and a low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis. Cardiac Ablation Solutions revenue increased 71%, with a 128% increase in the U.S., driven by the pulsed field ablation (PFA) portfolio.
The Neuroscience Portfolio revenue reached $2.562 billion, a 4.5% increase as reported and 3.9% organically, with a high-single digit increase in Neuromodulation, a mid-single digit increase in Cranial & Spinal Technologies, and flat results in Specialty Therapies, all on an organic basis. The Medical Surgical Portfolio revenue was $2.171 billion, up 2.1% as reported and 1.3% organically, with low-single digit organic increases in both Surgical & Endoscopy and Acute Care & Monitoring. The Diabetes business saw revenue of $757 million, a 10.3% increase as reported and 7.1% organic.
Medtronic also highlighted the U.S. FDA approval for the Altaviva™ device, and the Hugo™ robotic-assisted surgery system met safety and effectiveness endpoints. Additionally, the U.S. FDA cleared the MiniMed™ 780G system for integration with the Instinct sensor and approved its use in Type 2 diabetes.
Thierry Piéton, Medtronic chief financial officer, stated that the company drove underlying efficiency gains in its gross margin and strategically increased investment in sales and marketing, leading to the raised full-year revenue and EPS guidance.
Medtronic will host a video webcast on November 18, at 8:00 a.m. EST to discuss the results. A replay of the webcast and transcript will be available on the company’s investor relations website.
Contact:
Erika Winkels
Public Relations
+1-763-526-8478
Ryan Weispfenning
Investor Relations
+1-763-505-4626
